Miquel Duran-Frigola
Miquel Duran-Frigola
Ersilia Open Source Initiative
Email verificata su ersilia.io - Home page
Citata da
Citata da
Widespread expansion of protein interaction capabilities by alternative splicing
X Yang, J Coulombe-Huntington, S Kang, GM Sheynkman, T Hao, ...
Cell 164 (4), 805-817, 2016
A reference map of the human binary protein interactome
K Luck, DK Kim, L Lambourne, K Spirohn, BE Begg, W Bian, R Brignall, ...
Nature 580 (7803), 402-408, 2020
Systems analysis of intracellular pH vulnerabilities for cancer therapy
E Persi, M Duran-Frigola, M Damaghi, WR Roush, P Aloy, JL Cleveland, ...
Nature communications 9 (1), 1-11, 2018
Isolation of human colon stem cells using surface expression of PTK7
P Jung, C Sommer, FM Barriga, SJ Buczacki, X Hernando-Momblona, ...
Stem Cell Reports 5 (6), 979-987, 2015
Recycling side-effects into clinical markers for drug repositioning
M Duran-Frigola, P Aloy
Genome Medicine 4 (1), 1-4, 2012
Analysis of chemical and biological features yields mechanistic insights into drug side effects
M Duran-Frigola, P Aloy
Chemistry & biology 20 (4), 594-603, 2013
Structural systems pharmacology: the role of 3D structures in next-generation drug development
M Duran-Frigola, R Mosca, P Aloy
Chemistry & biology 20 (5), 674-684, 2013
Residues coevolution guides the systematic identification of alternative functional conformations in proteins
P Sfriso, M Duran-Frigola, R Mosca, A Emperador, P Aloy, M Orozco
Structure 24 (1), 116-126, 2016
Drug sensitivity in cancer cell lines is not tissue-specific
S Jaeger, M Duran-Frigola, P Aloy
Molecular cancer 14 (1), 1-4, 2015
Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker
M Duran-Frigola, E Pauls, O Guitart-Pla, M Bertoni, V Alcalde, D Amat, ...
Nature Biotechnology 38 (9), 1087-1096, 2020
IntSide: a web server for the chemical and biological examination of drug side effects
T Juan-Blanco, M Duran-Frigola, P Aloy
Bioinformatics 31 (4), 612-613, 2015
A chemo-centric view of human health and disease
M Duran-Frigola, D Rossell, P Aloy
Nature communications 5 (1), 1-11, 2014
Dual fluorescence in 9-amino-2, 7, 12, 17-tetraphenylporphycene
M Duran-Frigola, R Tejedor-Estrada, D Sánchez-García, S Nonell
Physical Chemistry Chemical Physics 13 (21), 10326-10332, 2011
Detecting similar binding pockets to enable systems polypharmacology
M Duran-Frigola, L Siragusa, E Ruppin, X Barril, G Cruciani, P Aloy
PLoS computational biology 13 (6), e1005522, 2017
Systems-Wide Prediction of Enzyme Promiscuity Reveals a New Underground Alternative Route for Pyridoxal 5’-Phosphate Production in E. coli
MA Oberhardt, R Zarecki, L Reshef, F Xia, M Duran-Frigola, R Schreiber, ...
PLoS computational biology 12 (1), e1004705, 2016
Systematic identification of molecular links between core and candidate genes in breast cancer
R Arroyo, G Suńé, A Zanzoni, M Duran-Frigola, V Alcalde, TH Stracker, ...
Journal of molecular biology 427 (6), 1436-1450, 2015
Modifications of microvascular EC surface modulate phototoxicity of a porphycene anti-ICAM-1 immunoconjugate; therapeutic implications
E Rosŕs, P Santomá, M Duran-Frigola, B Hernandez, MC Llinŕs, ...
Langmuir 29 (31), 9734-9743, 2013
Formatting biological big data for modern machine learning in drug discovery
M Duran‐Frigola, A Fernández‐Torras, M Bertoni, P Aloy
Wiley Interdisciplinary Reviews: Computational Molecular Science, e1408, 2018
Drug repositioning beyond the low-hanging fruits
M Duran-Frigola, L Mateo, P Aloy
Current Opinion in Systems Biology 3, 95-102, 2017
Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization
G Moncunill, A Scholzen, M Mpina, A Nhabomba, AB Hounkpatin, ...
Science translational medicine 12 (543), 2020
Il sistema al momento non puň eseguire l'operazione. Riprova piů tardi.
Articoli 1–20